Valuation
- Market cap
- 0
- Revenue TTM
- $1,080,000
- Net income TTM
- $-5,060,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -468.52%
- Debt to equity
- 0.00
Trading
- Volume
- 100
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 152,000
- Stochastic %K
- —
- Beta
- 2.15
- Analysts
- —
- Price target
- —
Company profile
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of healt...
Show more
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 41 21 566 5772
- Website
- https://www.mymetics.com
- Address
- ROUTE DE LA CORNICHE 4, Epalinges, Switzerland
Latest news
No headlines yet.
